Join
Live feed
·
PRReleasevia Quantisnow
Kymera Therapeutics Inc. logo

Kymera to Hold Webcast and Conference Call Discussing Data from its KT-474 Phase 1 Trial to Be Presented at the 4th Annual Targeted Protein Degradation Summit on October 27th

ByQuantisnow·Wall Street's wire, on your screen.
KYMR· Kymera Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track KYMR (Kymera Therapeutics Inc.) and more on Quantisnow.